Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Wang

Showing results (511-520 of 603) with videos related to

Pageof 61
Sort By:
Blood Advances|June 15, 2025
A phase 2 study of obinutuzumab combined with lenalidomide in previously untreated high tumor burden follicular lymphomaNeha Akkad, Lei Feng, Jason R Westin, et al.
Plos One|November 9, 2013
Antigen presenting cell-mediated expansion of human umbilical cord blood yields log-scale expansion of natural killer cells with anti-myeloma activityNina Shah, Beatriz Martin-Antonio, Hong Yang, et al.
Lancet (London, England)|September 5, 2020
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design studyJeremy S Abramson, M Lia Palomba, Leo I Gordon, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 3, 2014
Pegylated liposomal doxorubicin replacing conventional doxorubicin in standard R-CHOP chemotherapy for elderly patients with diffuse large B-cell lymphoma: an open label, single arm, phase II trialYasuhiro Oki, Michael S Ewer, Daniel J Lenihan, et al.
International Journal of Cancer|May 19, 2023
Treatment patterns and clinical outcomes of mantle cell lymphoma: A retrospective cohort study by CHOICEDongfeng Zeng, Yu Fang, Yue Fei, et al.
Cancer Medicine|May 10, 2025
Association Between Pre-Diagnostic Delay and Survival Among Patients With Esophageal and Gastric Cancer Treated With Curative Intent During the COVID19 PandemicXin Wang, Yvonne Bach, Katherine Lajkosz, et al.
Journal of the American Academy of Dermatology|May 21, 2020
Deep learning for dermatologists: Part I. Fundamental conceptsDennis H Murphree, Pranav Puri, Huma Shamim, et al.
Spine|February 26, 2020
Outcomes and Complications With Age in Spondylolisthesis: An Evaluation of the Elderly From the Quality Outcomes DatabaseMichael Karsy, Andrew K Chan, Praveen V Mummaneni, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 30, 2018
T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple MyelomaJennifer N Brudno, Irina Maric, Steven D Hartman, et al.
Blood|July 27, 2012
A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myelomaDavid S Siegel, Thomas Martin, Michael Wang, et al.
Pageof 61

Showing results (511-520 of 603) with videos related to

Sort By:
Pageof 61
Blood Advances|June 15, 2025
A phase 2 study of obinutuzumab combined with lenalidomide in previously untreated high tumor burden follicular lymphomaNeha Akkad, Lei Feng, Jason R Westin, et al.
Plos One|November 9, 2013
Antigen presenting cell-mediated expansion of human umbilical cord blood yields log-scale expansion of natural killer cells with anti-myeloma activityNina Shah, Beatriz Martin-Antonio, Hong Yang, et al.
Lancet (London, England)|September 5, 2020
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design studyJeremy S Abramson, M Lia Palomba, Leo I Gordon, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 3, 2014
Pegylated liposomal doxorubicin replacing conventional doxorubicin in standard R-CHOP chemotherapy for elderly patients with diffuse large B-cell lymphoma: an open label, single arm, phase II trialYasuhiro Oki, Michael S Ewer, Daniel J Lenihan, et al.
International Journal of Cancer|May 19, 2023
Treatment patterns and clinical outcomes of mantle cell lymphoma: A retrospective cohort study by CHOICEDongfeng Zeng, Yu Fang, Yue Fei, et al.
Cancer Medicine|May 10, 2025
Association Between Pre-Diagnostic Delay and Survival Among Patients With Esophageal and Gastric Cancer Treated With Curative Intent During the COVID19 PandemicXin Wang, Yvonne Bach, Katherine Lajkosz, et al.
Journal of the American Academy of Dermatology|May 21, 2020
Deep learning for dermatologists: Part I. Fundamental conceptsDennis H Murphree, Pranav Puri, Huma Shamim, et al.
Spine|February 26, 2020
Outcomes and Complications With Age in Spondylolisthesis: An Evaluation of the Elderly From the Quality Outcomes DatabaseMichael Karsy, Andrew K Chan, Praveen V Mummaneni, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 30, 2018
T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple MyelomaJennifer N Brudno, Irina Maric, Steven D Hartman, et al.
Blood|July 27, 2012
A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myelomaDavid S Siegel, Thomas Martin, Michael Wang, et al.
Pageof 61